Literature DB >> 35882785

Taurine and N-Bromotaurine in Topical Treatment of Psoriasis.

Anthony M Kyriakopoulos1, Markus Nagl2, Ramesh C Gupta3, Janusz Marcinkiewicz4.   

Abstract

Psoriasis is a chronic skin auto-inflammatory and systemic disorder. Novel treatments are needed to solve a plethora of cases refractory to current treatment regimens. N-bromotaurine (TauNH-Br), a natural taurine oxidizing derivative produced by inflammatory cells, has anti-inflammatory, antiproliferative, and antimicrobial properties. This evidence prompted us to use TauNH-Br as a local agent for treatment of therapy-refractory psoriasis. Two pustular-plaque psoriasis cases, unresponsive to systemic and local treatments, one with localized lesions and one with generalized lesions, were selected. Both applications primarily indicated a sufficient curative activity of 1% TauNH-Br in psoriasis lesions. Moreover, TauNH-Br co-administration with taurine and a novel olive oil formulation cut in half the time needed for TauNH-Br alone to cause the same regression of equivalent psoriasis plaque lesions in the same patient. Importantly, all adverse effects of TauNH-Br (erythema, itching, bleeding) could be minimized by the combination therapy. Periods of 2-7 weeks to achieve almost complete regression with this formulation were remarkably short as compared to conventional treatment regimens that both patients had followed previously. Of note, there was no relapse within 3 months of monitoring. Combination formulations containing TauNH-Br and olive oil could become an advantageous topical medication for treatment of psoriasis.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  N-bromotaurine; Olive oil; Sulfur metabolism; Taurine; Topical psoriasis treatment

Mesh:

Substances:

Year:  2022        PMID: 35882785     DOI: 10.1007/978-3-030-93337-1_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  49 in total

1.  The systemic autoinflammatory diseases: inborn errors of the innate immune system.

Authors:  S Brydges; D L Kastner
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

2.  Continuous infusion of methotrexate in children with acute leukemia.

Authors:  I Djerassi; S Farber; E Abir; W Neikirk
Journal:  Cancer       Date:  1967-02       Impact factor: 6.860

3.  [Chlorine covers on skin surfaces. I. Determination of the covering strength with the DPD cuvette method].

Authors:  W Gottardi; A Karl
Journal:  Zentralbl Hyg Umweltmed       Date:  1990-12

Review 4.  N-chlorotaurine, a natural antiseptic with outstanding tolerability.

Authors:  Waldemar Gottardi; Markus Nagl
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

5.  High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis.

Authors:  Didem Didar Balci; Nizami Duran; Burcin Ozer; Ramazan Gunesacar; Yusuf Onlen; Julide Zehra Yenin
Journal:  Eur J Dermatol       Date:  2009-03-13       Impact factor: 3.328

6.  Biological treatments for moderate-to-severe psoriasis: indirect comparison.

Authors:  M Galván-Banqueri; R Marín Gil; B Santos Ramos; F J Bautista Paloma
Journal:  J Clin Pharm Ther       Date:  2013-02-26       Impact factor: 2.512

Review 7.  Phenolic molecules in virgin olive oils: a survey of their sensory properties, health effects, antioxidant activity and analytical methods. An overview of the last decade.

Authors:  Alessandra Bendini; Lorenzo Cerretani; Alegria Carrasco-Pancorbo; Ana Maria Gómez-Caravaca; Antonio Segura-Carretero; Alberto Fernández-Gutiérrez; Giovanni Lercker
Journal:  Molecules       Date:  2007-08-06       Impact factor: 4.411

Review 8.  Glucocorticoid resistance in inflammatory diseases.

Authors:  Peter J Barnes; Ian M Adcock
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

9.  Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.

Authors:  Roland Arnitz; Markus Stein; Petra Bauer; Barbara Lanthaler; Herbert Jamnig; Sabine Scholl-Bürgi; Katharina Stempfl-Al-Jazrawi; Hanno Ulmer; Bernhard Baumgartner; Sabine Embacher; Simon Geisler; Johanna M Gostner; Bernhard Müllinger; Beate Kälz; Markus Nagl
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 10.  Risk of liver disease in methotrexate treated patients.

Authors:  Richard Conway; John J Carey
Journal:  World J Hepatol       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.